Acorda Therapeutics (ACOR) 33.34 $ACOR
Hedge fund honcho eyes Biogen patent covering top-selling Tecfidera
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 3:04PM CDT
BIIB: 423.57 (+1.46), SHPG: 253.58 (+3.70), ACOR: 33.34 (-1.33)
Acorda Presents Data on First Clinical Study of Remyelinating Antibody for Multiple Sclerosis at American Academy of Neurology Annual Meeting
Business Wire - Wed Apr 22, 6:30AM CDT
--Antibody detected in cerebrospinal fluid
ACOR: 33.34 (-1.33)
Acorda Therapeutics Named One of the Best Places to Work For in New York 2015
Business Wire - Wed Apr 22, 6:01AM CDT
Biotechnology leader Acorda Therapeutics, Inc. (Nasdaq:ACOR) has been named one of the best companies to work for in New York, based on an independent survey by the Best Companies Group (BCG). Acorda was named to the list for the fifth consecutive year.
ACOR: 33.34 (-1.33)
This New Hedge Fund Strategy Just Might Be Crazy Enough To Work
Matthew Frankel, The Motley Fool - Motley Fool - Sun Apr 19, 1:07PM CDT
Hedge funds use a lot of strategies to make money, but one manager is doing something we've never seen before in order to make a profit -- challenging a company's patents and shorting its stock simultaneously. How exactly does it work, and will it...
SHPG: 253.58 (+3.70), JAZZ: 186.13 (-0.41), ACOR: 33.34 (-1.33)
Will This Hedge Fund Manager Bring Down Your Biotech Stocks?
Selena Maranjian, The Motley Fool - Motley Fool - Sun Apr 19, 12:01PM CDT
Hedge-fund manager Kyle Bass. Image: Insider Monkey Many hedge-fund managers are "activist" ones. They load up on stock in particular companies until they have so many shares that they can put pressure on management to take actions they...
SHPG: 253.58 (+3.70), JAZZ: 186.13 (-0.41), ACOR: 33.34 (-1.33)
Top 50 Big Biotech Partnering and M&A Deal Trends Report 2015
M2 - Thu Apr 16, 10:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dxqgzt/top_50_big) has announced the addition of the "Top 50 Big Biotech Partnering and M&A Deal Trends" report to their offering. The Top 50 Big Biotech Partnering and M&A Deal Trends report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big biotech companies. Top 50 Big Biotech Partnering and M&A Deal Trends provides the user with the following key benefits: - Detailed partnering activity profiles for each of the top 50 big biotech companies - Over 300 charts showing a company's dealmaking activity since 2009, allowing quick identification potential partners - Partnering therapy focus revealed - Partnering activity since 2010 - number of deals per year - Full listing of partnering deals - Activity by deal type - Activity by industry sector - Activity by phase of development - Activity by technology type - Activity by therapeutic area - Comprehensive access to over 1,500 partnering deals as recorded at Current Agreement, together with contract documents if available - Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents - Understand the key deal terms the company has agreed in previous deals - Undertake due diligence to assess suitability of your proposed deal terms for partner companies Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Big biotech top 50 dealmaking activity Chapter 3 - Top big biotech deals by value Chapter 4 - Submitting Opportunities to Big biotech Chapter 5 - Forthcoming big biotech partnering events Chapter 6 - Big Biotech Company Profiles - 30 of the 50 companies - Acorda Therapeutics - Actavis - Actelion - Alexion Pharmaceuticals - Alkermes - Allergan - Amgen - Bavarian Nordic - Biocon - Biogen Idec - BioMarin Pharmaceuticals - Celgene - CSL - Cubist - Genmab - Gilead Sciences - Isis Pharmaceuticals - Jaxx Pharmaceuticals - LFB Group - Medivation - PDL BioPharma - Pharmacyclics - Questcor Pharmaceuticals - Regeneron Pharmaceuticals - Roche - Salix Pharmaceuticals - SciClone Pharmaceuticals - Seattle Genetics - Shire - Vertex Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/dxqgzt/top_50_big
BIIB: 423.57 (+1.46), VRTX: 132.85 (+0.65), SLXP: 172.96 (+0.15), AMGN: 169.10 (+0.64), ACOR: 33.34 (-1.33), ALKS: 62.60 (-0.24), PDLI: 7.07 (unch), AGN: 240.22 (+2.88), ISIS: 66.26 (-0.03), GILD: 104.18 (-1.02), ALXN: 188.19 (+1.41), SCLN: 8.99 (+0.04), REGN: 472.63 (+9.41), CELGZ: 2.87 (+0.04)
Alexion Up as Soliris Gains EU Nod for Label Updates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 4:00PM CDT
Alexion Pharmaceuticals, Inc. announced that the European Commission has approved updates to the EU label for Soliris.
CYTK: 7.29 (-0.09), ALXN: 188.19 (+1.41), ACOR: 33.34 (-1.33), AFFX: 12.57 (-0.13)
Adamas Pharma's Lead Candidate Gets Orphan Status in U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 1:30PM CDT
Adamas Pharmaceuticals, Inc.'s (ADMS) lead candidate ADS-5102 received orphan drug status in the U.S. for levodopa-induced dyskinesia.
CYTK: 7.29 (-0.09), ADMS: 17.62 (-0.21), ANIP: 69.79 (+1.24), ACOR: 33.34 (-1.33)
Horizon Pharma's Actimmune Gets Fast Track Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 12:50PM CDT
Horizon Pharma plc (HZNP) announced that the FDA has granted fast track status to Actimmune for the treatment of Friedreich's ataxia.
CYTK: 7.29 (-0.09), ANIP: 69.79 (+1.24), HZNP: 30.96 (+0.10), ACOR: 33.34 (-1.33)
Tekmira Up on Ebola Candidate Update from the FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 10:10AM CDT
The FDA has notified Tekmira (TKMR) that it has modified the partial clinical hold on the IND for TKM-Ebola.
SRPT: 13.52 (+0.04), TKMR: 18.38 (-0.14), GSK: 46.57 (-0.67), ACOR: 33.34 (-1.33)
OvaScience (OVAS) Looks Good: Stock Up 8.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 8:11AM CDT
OvaScience, Inc. (OVAS) was a big mover last session, as the company saw its shares rise over 8% on the day.
OVAS: 29.85 (-0.24), ACOR: 33.34 (-1.33)
Ocular Therapeutix Slumps 19% after Negative Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 08, 4:10PM CDT
Ocular Therapeutix (OCUL) crumbled after announcing disappointing results from its second phase III study on its pipeline candidate OTX-DP.
CYTK: 7.29 (-0.09), ACOR: 33.34 (-1.33), AFFX: 12.57 (-0.13), OCUL: 25.90 (-0.05)
Hospira Slammed with Another Warning Letter by the FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 08, 4:00PM CDT
Hospira Inc. (HSP) received disappointing news when the FDA slammed a warning letter related to the company's manufacturing facility in Liscate, Italy.
PFE: 34.93 (+0.04), ACOR: 33.34 (-1.33), AFFX: 12.57 (-0.13), HSP: 87.80 (+0.04)
Acorda Therapeutics Down 11.5% Since SmarTrend Downtrend Call (ACOR)
Comtex SmarTrend(R) - Wed Apr 08, 11:36AM CDT
SmarTrend identified a Downtrend for Acorda Therapeutics (NASDAQ:ACOR) on February 10th, 2015 at $38.46. In approximately 2 months, Acorda Therapeutics has returned 11.54% as of today's recent price of $34.02.
ACOR: 33.34 (-1.33)
Gilead Submits Regulatory Application for HIV Drug in U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 08, 10:00AM CDT
Gilead Sciences announced that it has submitted a new drug application to the FDA for two doses of a fixed-dose combination of Emtriva and tenofovir alafenamide.
CYTK: 7.29 (-0.09), JNJ: 100.43 (+0.13), GILD: 104.18 (-1.02), ACOR: 33.34 (-1.33)
Alkermes Reports Encouraging Data on Schizophrenia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 07, 5:08PM CDT
Alkermes announced encouraging top-line data from a phase II study on oral atypical antipsychotic candidate, ALKS 3831, for schizophrenia.
CYTK: 7.29 (-0.09), LLY: 72.30 (+0.09), ACOR: 33.34 (-1.33), ALKS: 62.60 (-0.24)
Repros Gets EU Update on Secondary Hypogonadism Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 07, 1:50PM CDT
Repros (RPRX) announced that the European Medicines Agency has granted eligibility to the submission of a marketing authorization application for enclomiphene citrate as a new active substance.
HZNP: 30.96 (+0.10), RPRX: 8.36 (-0.15), ABBV: 64.52 (+0.91), ACOR: 33.34 (-1.33)
Teva, Xenon Start Phase II Postherpetic Neuralgia Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 06, 8:40AM CDT
Teva (TEVA) and Xenon Pharmaceuticals (XENE) announced the enrolment of the first patient in a phase IIb study on TV-45070, being developed for the treatment of patients suffering from postherpetic neuralgia.
XENE: 14.25 (-0.66), AKRX: 53.70 (-1.69), TEVA: 63.01 (-1.15), ACOR: 33.34 (-1.33)
Repros' Secondary Hypogonadism Drug Under FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 4:24PM CDT
Repros' (RPRX) enclomiphene citrate product candidate is under review in the U.S. for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function.
HZNP: 30.96 (+0.10), RPRX: 8.36 (-0.15), ABBV: 64.52 (+0.91), ACOR: 33.34 (-1.33)
Shire - Kyle Bass's 2nd Target
IP Hawk - at Seeking Alpha - Thu Apr 02, 10:19AM CDT
SHPG: 253.58 (+3.70), ACOR: 33.34 (-1.33)
Hedge fund honcho eyes Biogen patent covering top-selling Tecfidera
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 3:04PM CDT
BIIB: 423.57 (+1.46), SHPG: 253.58 (+3.70), ACOR: 33.34 (-1.33)
Acorda Presents Data on First Clinical Study of Remyelinating Antibody for Multiple Sclerosis at American Academy of Neurology Annual Meeting
Business Wire - Wed Apr 22, 6:30AM CDT
--Antibody detected in cerebrospinal fluid
ACOR: 33.34 (-1.33)
Acorda Therapeutics Named One of the Best Places to Work For in New York 2015
Business Wire - Wed Apr 22, 6:01AM CDT
Biotechnology leader Acorda Therapeutics, Inc. (Nasdaq:ACOR) has been named one of the best companies to work for in New York, based on an independent survey by the Best Companies Group (BCG). Acorda was named to the list for the fifth consecutive year.
ACOR: 33.34 (-1.33)
This New Hedge Fund Strategy Just Might Be Crazy Enough To Work
Matthew Frankel, The Motley Fool - Motley Fool - Sun Apr 19, 1:07PM CDT
Hedge funds use a lot of strategies to make money, but one manager is doing something we've never seen before in order to make a profit -- challenging a company's patents and shorting its stock simultaneously. How exactly does it work, and will it...
SHPG: 253.58 (+3.70), JAZZ: 186.13 (-0.41), ACOR: 33.34 (-1.33)
Will This Hedge Fund Manager Bring Down Your Biotech Stocks?
Selena Maranjian, The Motley Fool - Motley Fool - Sun Apr 19, 12:01PM CDT
Hedge-fund manager Kyle Bass. Image: Insider Monkey Many hedge-fund managers are "activist" ones. They load up on stock in particular companies until they have so many shares that they can put pressure on management to take actions they...
SHPG: 253.58 (+3.70), JAZZ: 186.13 (-0.41), ACOR: 33.34 (-1.33)
Top 50 Big Biotech Partnering and M&A Deal Trends Report 2015
M2 - Thu Apr 16, 10:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dxqgzt/top_50_big) has announced the addition of the "Top 50 Big Biotech Partnering and M&A Deal Trends" report to their offering. The Top 50 Big Biotech Partnering and M&A Deal Trends report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big biotech companies. Top 50 Big Biotech Partnering and M&A Deal Trends provides the user with the following key benefits: - Detailed partnering activity profiles for each of the top 50 big biotech companies - Over 300 charts showing a company's dealmaking activity since 2009, allowing quick identification potential partners - Partnering therapy focus revealed - Partnering activity since 2010 - number of deals per year - Full listing of partnering deals - Activity by deal type - Activity by industry sector - Activity by phase of development - Activity by technology type - Activity by therapeutic area - Comprehensive access to over 1,500 partnering deals as recorded at Current Agreement, together with contract documents if available - Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents - Understand the key deal terms the company has agreed in previous deals - Undertake due diligence to assess suitability of your proposed deal terms for partner companies Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Big biotech top 50 dealmaking activity Chapter 3 - Top big biotech deals by value Chapter 4 - Submitting Opportunities to Big biotech Chapter 5 - Forthcoming big biotech partnering events Chapter 6 - Big Biotech Company Profiles - 30 of the 50 companies - Acorda Therapeutics - Actavis - Actelion - Alexion Pharmaceuticals - Alkermes - Allergan - Amgen - Bavarian Nordic - Biocon - Biogen Idec - BioMarin Pharmaceuticals - Celgene - CSL - Cubist - Genmab - Gilead Sciences - Isis Pharmaceuticals - Jaxx Pharmaceuticals - LFB Group - Medivation - PDL BioPharma - Pharmacyclics - Questcor Pharmaceuticals - Regeneron Pharmaceuticals - Roche - Salix Pharmaceuticals - SciClone Pharmaceuticals - Seattle Genetics - Shire - Vertex Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/dxqgzt/top_50_big
BIIB: 423.57 (+1.46), VRTX: 132.85 (+0.65), SLXP: 172.96 (+0.15), AMGN: 169.10 (+0.64), ACOR: 33.34 (-1.33), ALKS: 62.60 (-0.24), PDLI: 7.07 (unch), AGN: 240.22 (+2.88), ISIS: 66.26 (-0.03), GILD: 104.18 (-1.02), ALXN: 188.19 (+1.41), SCLN: 8.99 (+0.04), REGN: 472.63 (+9.41), CELGZ: 2.87 (+0.04)
Alexion Up as Soliris Gains EU Nod for Label Updates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 4:00PM CDT
Alexion Pharmaceuticals, Inc. announced that the European Commission has approved updates to the EU label for Soliris.
CYTK: 7.29 (-0.09), ALXN: 188.19 (+1.41), ACOR: 33.34 (-1.33), AFFX: 12.57 (-0.13)
Adamas Pharma's Lead Candidate Gets Orphan Status in U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 1:30PM CDT
Adamas Pharmaceuticals, Inc.'s (ADMS) lead candidate ADS-5102 received orphan drug status in the U.S. for levodopa-induced dyskinesia.
CYTK: 7.29 (-0.09), ADMS: 17.62 (-0.21), ANIP: 69.79 (+1.24), ACOR: 33.34 (-1.33)
Horizon Pharma's Actimmune Gets Fast Track Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 12:50PM CDT
Horizon Pharma plc (HZNP) announced that the FDA has granted fast track status to Actimmune for the treatment of Friedreich's ataxia.
CYTK: 7.29 (-0.09), ANIP: 69.79 (+1.24), HZNP: 30.96 (+0.10), ACOR: 33.34 (-1.33)
Tekmira Up on Ebola Candidate Update from the FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 10:10AM CDT
The FDA has notified Tekmira (TKMR) that it has modified the partial clinical hold on the IND for TKM-Ebola.
SRPT: 13.52 (+0.04), TKMR: 18.38 (-0.14), GSK: 46.57 (-0.67), ACOR: 33.34 (-1.33)
OvaScience (OVAS) Looks Good: Stock Up 8.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 8:11AM CDT
OvaScience, Inc. (OVAS) was a big mover last session, as the company saw its shares rise over 8% on the day.
OVAS: 29.85 (-0.24), ACOR: 33.34 (-1.33)
Ocular Therapeutix Slumps 19% after Negative Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 08, 4:10PM CDT
Ocular Therapeutix (OCUL) crumbled after announcing disappointing results from its second phase III study on its pipeline candidate OTX-DP.
CYTK: 7.29 (-0.09), ACOR: 33.34 (-1.33), AFFX: 12.57 (-0.13), OCUL: 25.90 (-0.05)
Hospira Slammed with Another Warning Letter by the FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 08, 4:00PM CDT
Hospira Inc. (HSP) received disappointing news when the FDA slammed a warning letter related to the company's manufacturing facility in Liscate, Italy.
PFE: 34.93 (+0.04), ACOR: 33.34 (-1.33), AFFX: 12.57 (-0.13), HSP: 87.80 (+0.04)
Acorda Therapeutics Down 11.5% Since SmarTrend Downtrend Call (ACOR)
Comtex SmarTrend(R) - Wed Apr 08, 11:36AM CDT
SmarTrend identified a Downtrend for Acorda Therapeutics (NASDAQ:ACOR) on February 10th, 2015 at $38.46. In approximately 2 months, Acorda Therapeutics has returned 11.54% as of today's recent price of $34.02.
ACOR: 33.34 (-1.33)
Gilead Submits Regulatory Application for HIV Drug in U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 08, 10:00AM CDT
Gilead Sciences announced that it has submitted a new drug application to the FDA for two doses of a fixed-dose combination of Emtriva and tenofovir alafenamide.
CYTK: 7.29 (-0.09), JNJ: 100.43 (+0.13), GILD: 104.18 (-1.02), ACOR: 33.34 (-1.33)
Alkermes Reports Encouraging Data on Schizophrenia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 07, 5:08PM CDT
Alkermes announced encouraging top-line data from a phase II study on oral atypical antipsychotic candidate, ALKS 3831, for schizophrenia.
CYTK: 7.29 (-0.09), LLY: 72.30 (+0.09), ACOR: 33.34 (-1.33), ALKS: 62.60 (-0.24)
Repros Gets EU Update on Secondary Hypogonadism Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 07, 1:50PM CDT
Repros (RPRX) announced that the European Medicines Agency has granted eligibility to the submission of a marketing authorization application for enclomiphene citrate as a new active substance.
HZNP: 30.96 (+0.10), RPRX: 8.36 (-0.15), ABBV: 64.52 (+0.91), ACOR: 33.34 (-1.33)
Teva, Xenon Start Phase II Postherpetic Neuralgia Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 06, 8:40AM CDT
Teva (TEVA) and Xenon Pharmaceuticals (XENE) announced the enrolment of the first patient in a phase IIb study on TV-45070, being developed for the treatment of patients suffering from postherpetic neuralgia.
XENE: 14.25 (-0.66), AKRX: 53.70 (-1.69), TEVA: 63.01 (-1.15), ACOR: 33.34 (-1.33)
Repros' Secondary Hypogonadism Drug Under FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 4:24PM CDT
Repros' (RPRX) enclomiphene citrate product candidate is under review in the U.S. for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function.
HZNP: 30.96 (+0.10), RPRX: 8.36 (-0.15), ABBV: 64.52 (+0.91), ACOR: 33.34 (-1.33)
Shire - Kyle Bass's 2nd Target
IP Hawk - at Seeking Alpha - Thu Apr 02, 10:19AM CDT
SHPG: 253.58 (+3.70), ACOR: 33.34 (-1.33)
